
François Roubille

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4927883/publications.pdf Version: 2024-02-01



EDANÃSOIS POURILLE

#	Article	IF	CITATIONS
1	Evolution of right ventricular dysfunction and tricuspid regurgitation after TAVI: A prospective study. International Journal of Cardiology, 2022, , .	1.7	2
2	Low-dose corticosteroid therapy for cardiogenic shock in adults (COCCA): study protocol for a randomized controlled trial. Trials, 2022, 23, 4.	1.6	5
3	Colchicine: protection of the brain beyond the heart?. Expert Review of Clinical Immunology, 2022, 18, 101-103.	3.0	1
4	Impact of Daily Bedside Echocardiographic Assessment on Readmissions in Acute Heart Failure: A Randomized Clinical Trial. Journal of Clinical Medicine, 2022, 11, 2047.	2.4	0
5	Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry. ESC Heart Failure, 2022, 9, 408-419.	3.1	29
6	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	7.1	27
7	Simplified TAVR Procedure: How Far Is It Possible to Go?. Journal of Clinical Medicine, 2022, 11, 2793.	2.4	6
8	Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?. Journal of the American Heart Association, 2022, 11, .	3.7	2
9	One-Year Follow-Up of Patients Admitted for Emergency Coronary Angiography after Resuscitated Cardiac Arrest. Journal of Clinical Medicine, 2022, 11, 3738.	2.4	Ο
10	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 486-495.	4.0	44
11	Confidence vanished or impaired until distrust in the doctor-patient relationship because of COVID-19. Revue De Medecine Interne, 2021, 42, 58-60.	1.0	8
12	Acute Coronary Syndrome in the Era of SARS-CoV-2 Infection: A Registry of the French Group of Acute Cardiac Care. CJC Open, 2021, 3, 311-317.	1.5	12
13	Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism. Future Science OA, 2021, 7, FSO656.	1.9	9
14	Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1299-1306.	2.3	5
15	Nonâ€elcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Failure, 2021, 8, 789-798.	3.1	23
16	Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Failure, 2021, 8, 1509-1521.	3.1	14
17	Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction: A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol – The COVERT-MI Study. Cardiology, 2021, 146, 151-160.	1.4	12
18	Pheochromocytoma in a patient presenting with ventricular fibrillation and carotid dissection: a case report. European Heart Journal - Case Reports, 2021, 5, ytab012.	0.6	3

#	Article	IF	CITATIONS
19	A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure. ESC Heart Failure, 2021, 8, 799-801.	3.1	1
20	Conception and bicentric validation of the proSCANNED score, a simplified bedside prognostic score for Heart Failure patients. Scientific Reports, 2021, 11, 6179.	3.3	0
21	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. Circulation Genomic and Precision Medicine, 2021, 14, e003183.	3.6	7
22	Idarucizumab (Praxbind [®]) for dabigatran reversal in patients undergoing heart transplantation: a cohort of tenÂpatients. Future Science OA, 2021, 7, FSO689.	1.9	3
23	Transcatheter aortic valve replacement performed with selective telemetry monitoring: A prospective study. International Journal of Cardiology, 2021, 330, 158-163.	1.7	2
24	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2187-2199.	2.8	35
25	Coronavirus disease vaccination in heart failure: No time to waste. Archives of Cardiovascular Diseases, 2021, 114, 434-438.	1.6	6
26	Nonculprit Artery Myocardial Infarction and Complex Coronary Lesions in Anterior ST-Elevated Myocardial Infarction Patients: Data from the CIRCUS Study. Cardiology, 2021, 146, 728-736.	1.4	0
27	Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HFÂregistry. Future Science OA, 2021, 7, FSO697.	1.9	3
28	Sacubitrilâ€valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTOâ€SAS study. ESC Heart Failure, 2021, 8, 2513-2526.	3.1	15
29	Analytical assessment and performance of the 0/3h algorithm with novel high sensitivity cardiac troponin I. Clinica Chimica Acta, 2021, 519, 111-117.	1.1	2
30	Compared Outcomes of ST-Segment–Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. Circulation: Cardiovascular Interventions,	3.9	20
31	2021, 14, e011314. Vaccination for Respiratory Infections in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10, 4311.	2.4	6
32	Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 2021, 144, 859-869.	1.6	74
33	Could a Multi-Marker and Machine Learning Approach Help Stratify Patients with Heart Failure?. Medicina (Lithuania), 2021, 57, 996.	2.0	1
34	Colchicine reduces atherosclerotic plaque vulnerability in rabbits. Atherosclerosis Plus, 2021, 45, 1-9.	0.7	6
35	Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study. International Journal of Cardiology, 2021, 344, 213-219.	1.7	3
36	The COVID-19 Pandemic Led to a Small Increase in Changed Mentality Regarding Infection Risk without Any Change in Willingness to Be Vaccinated in Chronic Diseases Patients. Journal of Clinical Medicine, 2021, 10, 3967.	2.4	6

#	Article	IF	CITATIONS
37	Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis. European Journal of Cancer, 2021, 155, 25-27.	2.8	8
38	Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol. Medicina (Lithuania), 2021, 57, 1047.	2.0	3
39	Colchicine et syndromes coronariens aigus et chroniques. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2021, 2021, 7-10.	0.0	0
40	Additive value of bioclinical risk scores to high sensitivity troponins-only strategy in acute coronary syndrome. Clinica Chimica Acta, 2021, 523, 273-284.	1.1	1
41	PRADOC: a trial on the efficiency of a transition care management plan for hospitalized patients with heart failure in France. ESC Heart Failure, 2021, 8, 1649-1655.	3.1	3
42	Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10, 5387.	2.4	2
43	Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists. Journal of Clinical Medicine, 2021, 10, 5938.	2.4	3
44	Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Lithuania), 2021, 57, 1376.	2.0	1
45	Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: A prospective study. IJC Heart and Vasculature, 2021, 37, 100919.	1.1	5
46	Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. European Heart Journal, 2020, 41, 858-866.	2.2	32
47	sST2 as a value-added biomarker in heart failure. Clinica Chimica Acta, 2020, 501, 120-130.	1.1	40
48	Letter on â€~Pharmacyâ€based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM HF randomized controlled trial'. European Journal of Heart Failure, 2020, 22, 565-565.	7.1	0
49	Understanding the effects of COVID-19 on health care and systems. Lancet Public Health, The, 2020, 5, e524.	10.0	31
50	Acute cardiovascular diseases may be less likely to be considered because of the COVID-19 pandemic – our duty is first to alert, then to analyse more deeply: Response to a letter entitled "Severity of cardiovascular diseases during the COVID-19 pandemic―from T.Âlmamura. Archives of Cardiovascular Diseases, 2020, 113, 486-487.	1.6	1
51	Multimarker approach including CRP, sST2 and GDFâ€15 for prognostic stratification in stable heart failure. ESC Heart Failure, 2020, 7, 2230-2239.	3.1	34
52	Predictive value of early cardiac magnetic resonance imaging functional and geometric indexes for adverse left ventricular remodelling in patients with anterior ST-segment elevation myocardial infarction: A report from the CIRCUS study. Archives of Cardiovascular Diseases, 2020, 113, 710-720.	1.6	10
53	Colchicine for Secondary Cardiovascular Prevention in Coronary Disease. Circulation, 2020, 142, 1901-1904.	1.6	19
54	Colchicine and myocardial infarction: A review. Archives of Cardiovascular Diseases, 2020, 113, 652-659.	1.6	21

#	Article	IF	CITATIONS
55	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal, 2020, 41, 4092-4099.	2.2	174
56	Reperfusion therapies in pulmonary embolism–state of the art and expert opinion: A position paper from the "Unité de Soins Intensifs de Cardiologie―group of the French Society of Cardiology. Archives of Cardiovascular Diseases, 2020, 113, 749-759.	1.6	5
57	Total Burden of Events. Journal of the American College of Cardiology, 2020, 76, 1671-1673.	2.8	1
58	Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size. Scientific Reports, 2020, 10, 13597.	3.3	3
59	Myocardial Injury After Balloon Predilatation Versus Direct Transcatheter Aortic Valve Replacement: Insights From the DIRECTAVI Trial. Journal of the American Heart Association, 2020, 9, e018405.	3.7	7
60	One train may hide another: Acute cardiovascular diseases could be neglected because of the COVID-19 pandemic. Archives of Cardiovascular Diseases, 2020, 113, 303-307.	1.6	58
61	All rise! Orthostatic hypotension in heart failure: reply. European Journal of Heart Failure, 2020, 22, 1742-1742.	7.1	0
62	Clomiphene misuse and risk of severe cardiovascular events. European Journal of Clinical Pharmacology, 2020, 76, 901-902.	1.9	2
63	STADEâ€HF (sST2 As a help for management of HF): a pilot study. ESC Heart Failure, 2020, 7, 774-778.	3.1	8
64	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease. Europace, 2020, 22, 1600-1600.	1.7	2
65	Effects of an individualized exercise training program on severity markers of obstructive sleep apnea syndrome: a randomised controlled trial. Sleep Medicine, 2020, 70, 33-42.	1.6	17
66	Prior Balloon Valvuloplasty Versus Direct Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 594-602.	2.9	36
67	Organization of intensive cardiac care units in Europe: Results of a multinational survey. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 993-1001.	1.0	8
68	Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial. Canadian Journal of Cardiology, 2020, 36, 1805-1814.	1.7	10
69	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	7.1	66
70	The 50â€yearâ€old pulmonary artery catheter: the tale of a foretold death?. ESC Heart Failure, 2020, 7, 783-785.	3.1	1
71	Post resuscitation electrocardiogram for coronary angiography indication after out-of-hospital cardiac arrest. International Journal of Cardiology, 2020, 310, 73-79.	1.7	5
72	Intraâ€aortic balloon pump: is the technique really outdated?. ESC Heart Failure, 2020, 7, 1025-1030.	3.1	8

#	Article	IF	CITATIONS
73	Trials of mechanical circulatory support with percutaneous axial flow pumps in cardiogenic shock complicating acute myocardial infarction: Mission impossible?. Archives of Cardiovascular Diseases, 2020, 113, 448-460.	1.6	5
74	Telemonitoring versus standard care in heart failure: a randomised multicentre trial. European Journal of Heart Failure, 2020, 22, 985-994.	7.1	76
75	By half decrease of cardiovascular mortality in a Western country between 2000 and 2015: A contrasted picture advocating for a better management of comorbidities. International Journal of Cardiology, 2020, 318, 145-146.	1.7	0
76	Absolute Change in High Sensitivity Cardiac Troponin I for Three Hours is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department: How to Get to Best Benefit From HS-Troponins in Clinical Practice?. Annals of Laboratory Medicine, 2020, 40, 488-489.	2.5	0
77	Absolute Change in High Sensitivity Cardiac Troponin I for Three Hours is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department: How to Get to Best Benefit From HS-Troponins in Clinical Practice?. Annals of Laboratory Medicine, 2020, 40, 488-489.	2.5	0
78	Effects of remote ischemic conditioning on kidney injury in at-risk patients undergoing elective coronary angiography (PREPARE study): a multicenter, randomized clinical trial. Scientific Reports, 2019, 9, 11985.	3.3	8
79	Extracorporeal membrane oxygenation support in acute circulatory failure: A plea for regulation and better organization. Archives of Cardiovascular Diseases, 2019, 112, 441-449.	1.6	6
80	Management of valvulopathies with acute severe heart failure and cardiogenic shock. Archives of Cardiovascular Diseases, 2019, 112, 773-780.	1.6	25
81	Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. American Heart Journal, 2019, 214, 97-106.	2.7	20
82	Design and preliminary results of FRENSHOCK 2016: A prospective nationwide multicentre registry on cardiogenic shock. Archives of Cardiovascular Diseases, 2019, 112, 343-353.	1.6	30
83	Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 124, 90-97.	1.6	11
84	How should we implement the recommendations of the Acute Cardiovascular Care Association in in intensive cardiac care units in France?. Archives of Cardiovascular Diseases, 2019, 112, 79-81.	1.6	0
85	Letter on â€~ldarucizumab for the reversal of dabigatran in patients undergoing heart transplantation'. European Journal of Heart Failure, 2019, 21, 818-818.	7.1	2
86	Which high-sensitivity troponin variable best characterizes infarct size and microvascular obstruction?. Archives of Cardiovascular Diseases, 2019, 112, 334-342.	1.6	8
87	P1658Pharmacological treatment of patients with HFrEF: is it really optimized in case of CRT and/or ICD implantation?. European Heart Journal, 2019, 40, .	2.2	0
88	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2019, 381, 2497-2505.	27.0	1,696
89	132Imaging criteria for the diagnosis of heart failure with midrange and preserved LVEF in the real life. European Heart Journal, 2019, 40, .	2.2	0
90	Is hypertriglyceridemia atherogenic?. Current Opinion in Lipidology, 2019, 30, 291-299.	2.7	11

François Roubille

#	Article	IF	CITATIONS
91	Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure. Clinica Chimica Acta, 2019, 490, 167-171.	1.1	22
92	Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety. American Journal of Cardiovascular Drugs, 2019, 19, 1-10.	2.2	2
93	Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. Joint Bone Spine, 2019, 86, 49-54.	1.6	21
94	Cardiologie et sommeil. , 2019, , 299-311.		0
95	Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO AS study design. ESC Heart Failure, 2018, 5, 222-230.	3.1	19
96	Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. Contemporary Clinical Trials, 2018, 66, 45-50.	1.8	7
97	Reply concerning "Colchicine in coronary artery disease: Role of anti-inflammatory medications redefined― Prime time for anti-inflammatory agents for the management of cardiovascular diseases. International Journal of Cardiology, 2018, 254, 52.	1.7	0
98	Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Archives of Cardiovascular Diseases, 2018, 111, 582-590.	1.6	20
99	Assessment of the area at risk after acute myocardial infarction using 123I-MIBG SPECT: Comparison with the angiographic APPROACH-score. Journal of Nuclear Cardiology, 2018, 25, 572-580.	2.1	15
100	Obstructive sleep apnoea: from respiratory events to coronary microvascular dysfunction. Acta Cardiologica, 2018, 73, 319-324.	0.9	7
101	Editor's Choice - Acute Cardiovascular Care Association Position Paper on Intensive Cardiovascular Care Units: An update on their definition, structure, organisation and function. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 80-95.	1.0	72
102	Circulatory Support with Extracorporeal Membrane Oxygenation and/or Impella for Cardiogenic Shock During Myocardial Infarction. ASAIO Journal, 2018, 64, 708-714.	1.6	40
103	Admissions to intensive cardiac care units in France in 2014. Medicine (United States), 2018, 97, e12677.	1.0	7
104	Is hypertriglyceridemia atherogenic?. Presse Medicale, 2018, 47, 757-763.	1.9	6
105	Management of advanced heart failure: a review. Expert Review of Cardiovascular Therapy, 2018, 16, 775-794.	1.5	6
106	2998Contemporary and real-life picture of cardiogenic shock in France: a descriptive analysis of the FRENSHOCK multicenter prospective registry. European Heart Journal, 2018, 39, .	2.2	0
107	Management of acute heart failure: Contribution of daily bedside echocardiographic assessment on therapy adjustment with impact measure on the 30-day readmission rate (JECICA). Contemporary Clinical Trials Communications, 2018, 12, 103-108.	1.1	2
108	Letter to the editor concerning "comparative prognostic value of postprocedural creatine kinase myocardial band and highâ€sensitivity troponin T in patients with nonâ€STâ€segment elevation myocardial infarction undergoing percutaneous coronary intervention― Catheterization and Cardiovascular Interventions, 2018, 92, 633-634.	1.7	0

#	Article	IF	CITATIONS
109	An hs-TNT Second Peak Associated with High CRP at Day 2 Appears as Potential Biomarkers of Micro-Vascular Occlusion on Magnetic Resonance Imaging after Reperfused ST-Segment Elevation Myocardial Infarction. Cardiology, 2018, 140, 227-236.	1.4	7
110	Optimization of a simultaneous dual-isotope 201Tl/123I-MIBG myocardial SPECT imaging protocol with a CZT camera for trigger zone assessment after myocardial infarction for routine clinical settings: Are delayed acquisition and scatter correction necessary?. Journal of Nuclear Cardiology, 2017, 24, 1361-1369.	2.1	31
111	Description of acute cardiac care in 2014: A French nation-wide database on 277,845 admissions in 270 ICCUs. International Journal of Cardiology, 2017, 240, 433-437.	1.7	14
112	Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. International Journal of Cardiology, 2017, 240, 347-353.	1.7	46
113	Cardiogenic shock management: Still a challenge and a need for large-registry data. Archives of Cardiovascular Diseases, 2017, 110, 433-438.	1.6	7
114	Anti-inflammatory drugs as promising cardiovascular treatments. Expert Review of Cardiovascular Therapy, 2017, 15, 109-125.	1.5	18
115	COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Archives of Cardiovascular Diseases, 2017, 110, 395-402.	1.6	81
116	Data on nation-wide activity in intensive cardiac care units in France in 2014. Data in Brief, 2017, 13, 166-170.	1.0	3
117	Prevalence of obstructive sleep apnoea in acute coronary syndrome: Routine screening in intensive coronary care units. Annales De Cardiologie Et D'Angeiologie, 2017, 66, 223-229.	0.6	3
118	A pulmonary embolism (PE) with an unexpected intracardiac mass but without shock: Should we use thrombolytic therapy? About a case of a 88 year old man with suspicion of PE. International Journal of Cardiology, 2017, 227, 892-893.	1.7	1
119	Impact of hyperventilation and apnea on myocardial oxygenation in patients with obstructive sleep apnea – An oxygenation-sensitive CMR study. Journal of Cardiology, 2017, 69, 489-494.	1.9	18
120	Pericarditi acute e croniche. EMC - AKOS - Trattato Di Medicina, 2017, 19, 1-12.	0.0	0
121	Prior balloon valvuloplasty versus DIRECT transcatheter Aortic Valve Implantation (DIRECTAVI): study protocol for a randomized controlled trial. Trials, 2017, 18, 303.	1.6	11
122	P2725Description of acute cardiac care in 2014: A French nation-wide database on 277,845 admissions in 270 ICCUs. European Heart Journal, 2017, 38, .	2.2	0
123	Heart Involvement in a Woman Treated with Hydroxychloroquine for Systemic Lupus Erythematosus Revealing Fabry Disease. Journal of Rheumatology, 2016, 43, 997-998.	2.0	13
124	Feasibility and Safety of Transcatheter Aortic Valve Implantation Performed Without Intensive Care Unit Admission. American Journal of Cardiology, 2016, 118, 99-106.	1.6	20
125	Does ivabradine balance dobutamine effects in cardiogenic shock? A promising new strategy. Acta Physiologica, 2016, 218, 73-77.	3.8	5
126	Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. Journal of Cardiology, 2016, 67, 248-253.	1.9	18

#	Article	IF	CITATIONS
127	A rare cause of acute coronary syndrome in a handyman. International Journal of Cardiology, 2016, 203, 594-595.	1.7	2
128	Copeptin and high-sensitivity cardiac troponin to exclude severe coronary stenosis in patients with chest pain and coronary artery disease. American Journal of Emergency Medicine, 2016, 34, 493-498.	1.6	2
129	Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 354-363.	1.0	56
130	Multi-Marker Strategy in Heart Failure: Combination of ST2 and CRP Predicts Poor Outcome. PLoS ONE, 2016, 11, e0157159.	2.5	31
131	Micro-RNAs as promising biomarkers in cardiac diseases. Annals of Translational Medicine, 2016, 4, 551-551.	1.7	6
132	Kinetics of high-sensitivity cardiac troponin T or troponin I compared to creatine kinase in patients with revascularized acute myocardial infarction. Clinical Chemistry and Laboratory Medicine, 2015, 53, 707-14.	2.3	38
133	Ivabradine: A promising drug in cardiogenic shock to prevent the undesirable sinus tachycardia induced by dobutamine?. International Journal of Cardiology, 2015, 178, 308-310.	1.7	4
134	Collagen plug-based vascular closure devices do not decrease vascular and bleeding complications occurring after balloon aortic valvuloplasty. Archives of Cardiovascular Diseases, 2015, 108, 250-257.	1.6	3
135	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	2.2	1,768
136	Investigational drugs targeting cardiac fibrosis. Expert Review of Cardiovascular Therapy, 2014, 12, 111-125.	1.5	59
137	No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission. European Heart Journal, 2014, 35, 1675-1682.	2.2	41
138	New Drug Avenues for Cardioprotection in Patients with Acute Myocardial Infarction. American Journal of Cardiovascular Drugs, 2014, 14, 73-77.	2.2	11
139	Apoptosis following myocardial infarction: cardiomyocytes and beyond – comment on the paper †Dynamics of serumâ€induced endothelial cell apoptosis in patients with myocardial Infarction' by Forteza <i>etÂal</i> European Journal of Clinical Investigation, 2014, 44, 1-3.	3.4	5
140	The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis, 2014, 236, 277-285.	0.8	14
141	Inflammation and the heart – prime time for new therapeutic approaches. Expert Opinion on Emerging Drugs, 2013, 18, 259-261.	2.4	11
142	What is the Role of Erythropoietin in Acute Myocardial Infarct? Bridging the Gap Between Experimental Models and Clinical Trials. Cardiovascular Drugs and Therapy, 2013, 27, 315-331.	2.6	21
143	Management of pericarditis and myocarditis: Could heart-rate-reducing drugs hold a promise?. Archives of Cardiovascular Diseases, 2013, 106, 672-679.	1.6	10
144	Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?. Medical Hypotheses, 2013, 81, 202-206.	1.5	20

#	Article	IF	CITATIONS
145	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. International Journal of Cardiology, 2013, 168, 4244-4248.	1.7	14
146	Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial. Archives of Cardiovascular Diseases, 2013, 106, 135-145.	1.6	10
147	Cardioprotection—Time to Take Into Account Clinical Complexity: The Case of Antiplatelet Agents. Cardiovascular Drugs and Therapy, 2013, 27, 105-107.	2.6	4
148	Influence of traditional cardiovascular risk factors on infarct size and on mechanical ischemic postconditionning in STEMI patients. European Heart Journal, 2013, 34, P1282-P1282.	2.2	0
149	New Therapeutic Targets in Cardiology. Circulation, 2013, 127, 1986-1996.	1.6	59
150	Does pre-PCI angiographic TIMI flow in the culprit coronary artery influence infarct size and microvascular obstruction in acute STEMI patients?. European Heart Journal, 2013, 34, P1295-P1295.	2.2	0
151	Colchicine: An Old Wine in a New Bottle?. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 14-23.	1.1	75
152	Depletion of proBNP1-108 in Patients with Heart Failure Prevents Cross-Reactivity with Natriuretic Peptides. PLoS ONE, 2013, 8, e75174.	2.5	7
153	Emerging Anti-inflammatory Therapies for Atherosclerosis. Current Pharmaceutical Design, 2013, 19, 5840-5849.	1.9	17
154	Editorial (Hot Topic: Anti-Inflammatory Drugs and the Heart Special Thematic). Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 2-2.	1.1	3
155	Down-regulation of the transcription factor ZAC1 upon pre- and postconditioning protects against I/R injury in the mouse myocardium. Cardiovascular Research, 2012, 94, 351-358.	3.8	14
156	Right phrenic stimulation due to defibrillator implantation: A rare cause. Archives of Cardiovascular Diseases, 2012, 105, 256-257.	1.6	0
157	Post-Conditioning Reduces Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2012, 59, 2175-2181.	2.8	194
158	Could heart rate play a role in pericardial inflammation?. Medical Hypotheses, 2012, 79, 512-515.	1.5	17
159	Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Research in Cardiology, 2012, 107, 275.	5.9	65
160	Delayed Postconditioning in the Mouse Heart In Vivo. Circulation, 2011, 124, 1330-1336.	1.6	80
161	Multiple coronary-left ventricular fistulae associated with apical hypertrophic cardiomyopathy: Coronary angiogram compared to coronary scan and cardiac magnetic resonance scan. Cardiology Journal, 2011, 18, 702-703.	1.2	3
162	Fatal Systemic Nocardia Infection Revealed by Cardiac Tamponade. Internal Medicine, 2010, 49, 135-137.	0.7	5

François Roubille

#	Article	IF	CITATIONS
163	MR delayed enhancement imaging findings in suspected acute myocarditis. European Radiology, 2010, 20, 65-72.	4.5	18
164	Recurrent severe acute apical-sparing left ventricular dysfunction in a young woman: Don't forget pheochromocytoma. Annales De Cardiologie Et D'Angeiologie, 2010, 59, 52-53.	0.6	3
165	Can troponin elevation predict worse prognosis in patients with acute pericarditis?. Annales De Cardiologie Et D'Angeiologie, 2010, 59, 1-7.	0.6	23
166	Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI. European Journal of Internal Medicine, 2010, 21, 131-136.	2.2	19
167	Acute myocarditis and Tumor Necrosis Factor Receptor-Associated Periodic (TRAP) syndrome: First case described and discussion. European Journal of Internal Medicine, 2009, 20, e25-e26.	2.2	10
168	Epstein Barr Virus (EBV) and Acute Myopericarditis in an Immunocompetent Patient: First Demonstrated Case and Discussion. Internal Medicine, 2008, 47, 627-629.	0.7	30
169	Likely Tuberculous Myocarditis Mimicking an Acute Coronary Syndrome. Internal Medicine, 2008, 47, 1699-1701.	0.7	11
170	Myocardial Expression of a Dominant-Negative Form of Daxx Decreases Infarct Size and Attenuates Apoptosis in an In Vivo Mouse Model of Ischemia/Reperfusion Injury. Circulation, 2007, 116, 2709-2717.	1.6	34